https://www.selleckchem.com/products/cnqx.html
Outcome data for CSII, which is approved for use in pregnancy and has been utilized for several decades, remain mixed. Current evidence, although limited, for commercially available and emerging technologies for the management of T1D in pregnancy holds promise for improving patient and fetal outcomes. HIGHLIGHTS The management of T1D in pregnancy has been enhanced in large part due to development of more effective glucose monitoring and insulin delivery systems. CGM has been demonstrated to improve glycemic control and minimize excursions
Like
Comment
Share
